Skip to main content

Table 2 Therapeutic efficacy of artesunate + amodiaquine, artesunate + sulphadoxine-pyrimethamine, and amodiaquine + sulphadoxine-pyrimethamine among children with uncomplicated malaria in Faladje, Mali

From: Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali

Characteristics AS+AQ (N= 131) AS+SP (N = 130) AQ+SP (N = 130)
PCR uncorrected responses on day 28: n (%)    
Failures 58 (44.3) 12 (9.2) 3(2.3)
   ETF 0 (0) 2(1.5) 0(0)
   LCF 14 (10.7) 2(1.5) 1(0.8)
   LPF 44 (33.6) 8(6.2) 2(1.5)
*ACPR 73 (55.7) 118 (90.8) 127(97.7)
PCR corrected responses on day 28: n; %    
Failures 6 (4.6) 4 (3.1) 1 (0.8)
   ETF 0 (0) 2(1.6) 0(0)
   LCF 2(1.5) 1(0.8) 0(0)
   LPF 4(3.1) 1(0.8) 1 (0.8)
**ACPR 124(95.4) 125(96.9) 129(99.2)
  1. AS+AQ, artesunate + amodiaquine; AS+SP, artesunate + sulphadoxine-pyrimethamine;
  2. AQ+SP, amodiaquine + sulphadoxine-pyrimethamine
  3. ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response.
  4. Failures are the combination of ETF, LCF, and LPF. Percentages are rounded to achieve 100% of totals.
  5. *X2 test: p < 0.001, AS+AQ vs. AS+SP; p < 0.001, AS+AQ vs. AQ+SP; p = 0.016, AS+SP vs. AQ+SP
  6. **X2 test: p = 0.17 for the comparison of the three treatment arms.